The puzzle of antiplatelet therapy in ACS: ticagrelor monotherapy is another missing piece

Graphical AbstractThe optimal antithrombotic therapy in patients after an acute coronary syndrome consists of balancing each patient's ischaemic and bleeding risk. Bleeding risk can be calculated using different risk scores and is influenced by the duration of dual antiplatelet therapy and the potency of the P2Y12 inhibitor prescribed. Ischaemic risk is influenced by comorbidities such as diabetes as well as procedural characteristics. By employing a personalized approach and considering P2Y12 inhibitor monotherapy, physicians may select the most suitable antithrombotic regimen after an acute coronary syndrome.Open in new tabDownload slide